Evidence map›Paper›PMID 29322065›Full record

ArticleMolecular therapy. Methods & clinical development2018

Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1.

Wannisa Khamaikawin, Saki Shimizu, Masakazu Kamata, Ruth Cortado, Yujin Jung, Jennifer Lam, Jing Wen, Patrick Kim, Yiming Xie, Sanggu Kim and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Modeling Unique Patients in Humanized Mice: Toward a Curative Strategy for HIV.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Wannisa KhamaikawinSchool of Nursing, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Saki ShimizuDivision of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Masakazu KamataDivision of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Ruth CortadoSchool of Nursing, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Yujin JungSchool of Nursing, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Jennifer LamSchool of Nursing, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Jing WenDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Patrick KimDivision of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Yiming XieDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Sanggu KimDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Hubert ArokiumDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Angela P PressonDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Irvin S Y ChenDivision of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Dong Sung AnDivision of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USBlack AIDS Institute · USUniversity of Utah · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
Viral Immunology CoreU19AI117941 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SYMONDS, GEOFFREY · 2015 to 2019
$10.6M
Genetic protection of hematopoietic stem cells for stable HIV controlR01AI100652 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AN, DONG SUNG · 2012 to 2016
$1.9M
Defining a therapeutic threshold in HSPC gene therapy for HIV-1 diseaseR00HL116234 · NHLBI · OHIO STATE UNIVERSITY · PI KIM, SANGGU · 2016 to 2018
$747k
Defining a therapeutic threshold in HSPC gene therapy for HIV-1 diseaseK99HL116234 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIM, SANGGU · 2012 to 2013
$178k
NHLBI NIH HHS K99 HL116234NHLBI NIH HHS R00 HL116234NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI100652NIAID NIH HHS U19 AI117941
6 · The paper itself

Abstract

Investigations of anti-HIV-1 human hematopoietic stem/progenitor cell (HSPC)-based gene therapy have been performed by HIV-1 challenge after the engraftment of gene-modified HSPCs in humanized mouse models. However, the clinical application of gene therapy is to treat HIV-1-infected patients. Here, we developed a new method to investigate an anti-HIV-1 HSPC-based gene therapy in humanized mice previously infected with HIV-1. First, humanized mice were infected with HIV-1. When plasma viremia reached >10

Indexed as

gene therapy for HIV/AIDSHPSC-based gene therapyhumanized mouse model

Identifiers

PMID29322065
PMCPMC5751878
OpenAlexW2773352887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.